Results 81 to 90 of about 4,935 (109)

Empirical Drug Dosage Validates Pharmacogenomic Associations in All of Us. [PDF]

Clin Transl Sci
Matthias J, Falaguera MJ, Altman RB.
europepmc   +1 more source

Application of a mouse model humanized for cytochrome P450-mediated drug metabolism to predict drug-drug interactions between a peptide and small molecule drugs. [PDF]

Drug Metab Dispos
Kapelyukh Y, Gabel-Jensen C, MacLeod AK, Daniel Coquelin KS, Stojanovski L, Frame L, Tavendale A, Henderson CJ, Read KD, Wolf CR, Säll C.   +10 more
europepmc   +1 more source

A Novel POR G88S Mutation Causes Severe PORD and Establishes a Critical Pharmacogenomic Risk Profile.

J Clin Endocrinol Metab
Rojas Velazquez MN, Lopez Dacal J, Jørgensen FS, Sanguineti N, Sharma K, Marino R, Pérez Garrido N, Vaiani E, Ramírez P, Scaglia P, Izquierdo A, Sansó G, Ropelato MG, Bergadá I, Rey RA, Grinspon RP, Pandey AV.   +16 more
europepmc   +1 more source

In vitro and clinical data demonstrate negligible risk of drug-drug interactions with opelconazole, a novel inhaled antifungal agent. [PDF]

J Antimicrob Chemother
Cass LMR, Ayrton J, Brüggemann RJ, Moore J, Martin U, Grey L, Hyman M, Berman L.   +7 more
europepmc   +1 more source

<i>CYP2C9</i> polymorphism is associated with susceptibility to ischemic stroke in a Chinese population. [PDF]

Ann Med
Zhang J, Jia H, Liu Y, Zhang Y, Nie H, Bao Q.   +5 more
europepmc   +1 more source

Implications of Genetic Elements on Type 2 Diabetes Mellitus Pathogenesis and Management. [PDF]

Endocrinol Diabetes Metab
Ngcobo NN, Sibiya NH.
europepmc   +1 more source

Prevalence of actionable pharmacogenomic variants in Brazilian patients with cancer. [PDF]

Front Pharmacol
Schuch JB, Botton MR, De Baumont AC, Curzel G, Cadore NA, Bordignon C, Rosa ML, Vasconcellos VF, Barros LAR, Souza CP, Barra WF, Louzeiro DLC, Notari A, de Menezes JJ, Liedke PER, Bertollo GA, Gongora ABL, Ascenco HG, Kowalski-Neto E, Oppermann CP, Werutsky G, Santos EM, Brandão FS, Freitas-Junior R, Nogueira-Rodrigues A, Mancini ALC, Bessel M, Macedo GS, Rosa DD.   +28 more
europepmc   +1 more source

The effect of salidroside, an active component of Rhodiola rosea, on the metabolic activity of rat and human cytochromes P450 in preclinical studies. [PDF]

Pharmacol Rep
Klaskova E, Jurica J, Danek PJ, Mlcuchova N, Eyrilmez SM, Borilova Linhartova P, Bednar D, Kamaraj R, Daniel WA, Zendulka O.   +9 more
europepmc   +1 more source

Comparison of cytochrome P450 activity and mRNA expression in canine vs. human hepatocytes after acetaminophen, diclofenac, or valproic acid exposure. [PDF]

J Vet Sci
Kang JR, Lee J, Suh HN.
europepmc   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Influence of cytochrome P-450 CYP2C9 polymorphisms on warfarin sensitivity and risk of over-anticoagulation in patients on long-term treatment

Blood, 2000
Abstract Cytochrome P-450 2C9 is the principle enzyme that terminates the anticoagulant effect of warfarin. Genetic polymorphisms inCYP2C9 producing variants with altered catalytic properties have been identified. Patients (n = 561) with a target international normalized ratio (INR) of 2.5 who had been treated with warfarin for more than
J, Taube, D, Halsall, T, Baglin
exaly   +3 more sources